Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Immucell (ICCC) EBITDA Margin (2016 - 2025)

Immucell (ICCC) has disclosed EBITDA Margin for 16 consecutive years, with 0.36% as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, EBITDA Margin rose 1087.0% year-over-year to 0.36%, compared with a TTM value of 8.39% through Sep 2025, down 375.0%, and an annual FY2024 reading of 6.19%, up 74.0% over the prior year.
  • EBITDA Margin was 0.36% for Q3 2025 at Immucell, down from 8.84% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 13.85% in Q1 2025 and bottomed at 65.46% in Q1 2023.
  • Average EBITDA Margin over 5 years is 10.48%, with a median of 6.63% recorded in 2021.
  • The sharpest move saw EBITDA Margin crashed -7497bps in 2023, then surged 6132bps in 2024.
  • Year by year, EBITDA Margin stood at 2.67% in 2021, then tumbled by -1664bps to 41.77% in 2022, then skyrocketed by 47bps to 21.94% in 2023, then surged by 137bps to 8.02% in 2024, then tumbled by -95bps to 0.36% in 2025.
  • Business Quant data shows EBITDA Margin for ICCC at 0.36% in Q3 2025, 8.84% in Q2 2025, and 13.85% in Q1 2025.